Option chain shows key data for ZyVersa Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ZyVersa Therapeutics.

ZyVersa Therapeutics (NASDAQ:ZVSA) Stock, Option Chain

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

YUMC

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BNOX

VMEO

VRCA

ZVSA

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Wall Street

S&amp;P 500 Gains 1%; Vimeo Shares Spike Higher

ALBT

Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

Contracts

Press Releases

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model

Health Care

Analyst Ratings

General

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases

Aditxt

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

GRI Bio

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

SILO Pharma

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

HC Wainwright & Co.

Screenshot 2024-03-29 at 1.05.42 AM

Biotech

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Comments

ZyVersa Therapeutics

ZyVersa Therapeutics (ZVSA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell